Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Toth Financial Advisory Corp

Toth Financial Advisory Corp increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1,450.0% during the 3rd quarter, Holdings Channel.com reports. The fund owned 1,550 shares of the pharmaceutical company’s stock after purchasing an additional 1,450 shares during the quarter. Toth Financial Advisory Corp’s holdings in Vertex Pharmaceuticals were worth $721,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of VRTX. Capital World Investors grew its stake in Vertex Pharmaceuticals by 17.2% during the 1st quarter. Capital World Investors now owns 25,567,184 shares of the pharmaceutical company’s stock worth $10,687,339,000 after buying an additional 3,761,414 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Vertex Pharmaceuticals by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 22,676,518 shares of the pharmaceutical company’s stock valued at $9,479,011,000 after acquiring an additional 394,338 shares during the period. Capital Research Global Investors raised its position in Vertex Pharmaceuticals by 61.0% in the 1st quarter. Capital Research Global Investors now owns 5,743,882 shares of the pharmaceutical company’s stock valued at $2,401,000,000 after purchasing an additional 2,176,218 shares during the last quarter. Jennison Associates LLC boosted its stake in Vertex Pharmaceuticals by 21.2% during the 1st quarter. Jennison Associates LLC now owns 4,782,374 shares of the pharmaceutical company’s stock worth $1,999,080,000 after purchasing an additional 837,461 shares during the period. Finally, Janus Henderson Group PLC grew its position in Vertex Pharmaceuticals by 10.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,584,315 shares of the pharmaceutical company’s stock worth $1,080,296,000 after purchasing an additional 244,336 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Down 1.0 %

Shares of VRTX stock opened at $478.09 on Tuesday. Vertex Pharmaceuticals Incorporated has a 1-year low of $341.90 and a 1-year high of $510.64. The firm’s 50-day simple moving average is $475.48 and its 200-day simple moving average is $460.75. The firm has a market cap of $123.40 billion, a P/E ratio of -235.51 and a beta of 0.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The business had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.66 billion. During the same quarter in the previous year, the business posted $3.53 EPS. The company’s quarterly revenue was up 6.1% on a year-over-year basis. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -2.11 EPS for the current year.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several recent research reports. Oppenheimer increased their target price on shares of Vertex Pharmaceuticals from $500.00 to $550.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Redburn Atlantic initiated coverage on Vertex Pharmaceuticals in a report on Thursday, June 27th. They issued a “buy” rating and a $545.00 target price on the stock. Raymond James reaffirmed a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. Wells Fargo & Company boosted their price objective on shares of Vertex Pharmaceuticals from $540.00 to $555.00 and gave the company an “overweight” rating in a research note on Monday, June 24th. Finally, JPMorgan Chase & Co. raised their target price on shares of Vertex Pharmaceuticals from $505.00 to $510.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $492.92.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the sale, the director now owns 40,000 shares of the company’s stock, valued at $20,320,000. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $508.00, for a total transaction of $2,689,860.00. Following the completion of the sale, the director now owns 40,000 shares in the company, valued at $20,320,000. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Carmen Bozic sold 2,280 shares of the company’s stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $488.46, for a total value of $1,113,688.80. Following the completion of the transaction, the chief marketing officer now directly owns 25,539 shares in the company, valued at approximately $12,474,779.94. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 14,285 shares of company stock worth $7,101,755. Corporate insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.